Effective January 1, 2026, CMS will apply the 36-month rule to all DMEPOS suppliers. If a majority ownership change occurs within 36 months of initial Medicare enrollment or a previous ownership change, the buyer cannot assume the supplier’s Medicare billing privileges. The supplier’s enrollment will be terminated, and the buyer must re-enroll as a new DMEPOS supplier and obtain accreditation.
CMS has also replaced the three-year accreditation cycle with mandatory annual reaccreditation surveys, increasing ongoing compliance costs.
Key M&A Implications
Transaction Friction Increases
- Buyers must carefully review Medicare enrollment timelines. Acquiring a supplier within the 36-month window may result in billing disruptions during re-enrollment.
Valuation Divergence Emerges
- Suppliers with established 36-month enrollment histories are significantly more valuable than newly enrolled suppliers. Anticipate reduced valuation multiples, inflated escrow structures, and earnouts contingent on successful enrollment.
Private Equity Roll-Ups Are Constrained
- The rule is intended to limit rapid ownership turnover, which is common in private equity roll-up strategies. Secondary buyouts within the 36-month window will be more difficult to complete.
Deal Structuring Becomes Critical
- Indirect ownership changes, such as acquiring a parent entity, may avoid triggering the rule. However, CMS may challenge aggressive structuring.
Multi-Location Platforms Are More Complex
- Each DMEPOS location requires separate enrollment, so platform acquisitions may involve multiple 36-month timelines, increasing due diligence complexity.
Higher Ongoing Compliance Costs
- Annual accreditation surveys introduce recurring regulatory costs and operational disruptions at each location.
Strategies Gain an Advantage
- Strategic buyers with established compliance infrastructure are better equipped to manage re-enrollment risk than financial sponsors.
Bottom Line
The CMS rule introduces structural challenges to DMEPOS M&A, particularly for newer suppliers and recently acquired assets. Anticipate slower deal velocity, valuation discounts for suppliers within the 36-month window, and increased diligence regarding Medicare enrollment history.